Case Report: Fatal pneumonitis caused by Camrelizumab and Erlotinib in a patient with metastatic pancreatic cancer
-
By
-
Yanyan Jiang
-
Lihong Ma
-
Bei Lu
-
Wei Tian
-
June 10, 2026
-
Clinical Scorecard: Case Study: Lethal Pneumonitis Induced by Camrelizumab and Erlotinib in a Patient with Metastatic Pancreatic Carcinoma
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Combination of immunotherapy (Camrelizumab) and targeted therapy (Erlotinib) with emphasis on potential risks. |
| Target Population | |
| Care Setting | |
Key Highlights
- Patient developed fatal pneumonitis after treatment with Camrelizumab and Erlotinib.
- Combination therapy was administered in the second-line setting.
- Patient was refractory to first-line chemotherapy (gemcitabine and nab-paclitaxel).
- Initial treatment response was stable but indicated resistance.
- Significant caution is advised when combining immunotherapy with Erlotinib.
Guideline-Based Recommendations
Diagnosis
Management
- Second-line treatment with FOLFIRI, Camrelizumab, and Erlotinib.
- Consideration of other second-line options based on patient condition.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patient received second-line therapy after failure of first-line chemotherapy, which showed initial stability but ultimately resistance.
Clinical Best Practices
- Exercise caution in administering Erlotinib following immune checkpoint inhibitor therapy.
- Monitor respiratory status closely in patients receiving combination therapy, especially for pneumonitis.
Related Resources & Content
